HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

18-dehydroxyl-17-demethoxyreblastatin

antineoplastic geldanamycin derivative; structure in first source

Also Known As:

WK88-1

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amides: 2428
  - Lactams: 2198
    - Macrocyclic Lactams: 28
      - 18-dehydroxyl-17-demethoxyreblastatin: 2
- Quinones: 434
  - Benzoquinones: 25
    - 18-dehydroxyl-17-demethoxyreblastatin: 2
Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Macrocyclic Lactams: 28
    - 18-dehydroxyl-17-demethoxyreblastatin: 2

Experts

1.	Hong, Young-Soo: 2 articles (10/2014 - 06/2014)
2.	Jang, Won-Jun: 2 articles (10/2014 - 06/2014)
3.	Jeong, Chul-Ho: 2 articles (10/2014 - 06/2014)
4.	Bae, Moon-Kyoung: 1 article (10/2014)
5.	Jeong, Joo-Won: 1 article (10/2014)
6.	Joo, Sang Hoon: 1 article (10/2014)
7.	Jung, Sung-Keun: 1 article (10/2014)
8.	Kang, Jong-Soon: 1 article (10/2014)
9.	Kundu, Joydeb K: 1 article (10/2014)
10.	Park, Gyu Hwan: 1 article (10/2014)

Related Diseases

1.	Neoplasms (Cancer) 10/01/2014 - "Administration of WK88-1 did not cause hepatotoxicity in animals and significantly reduced the growth of HCC827GR cells xenograft tumors in nude mice. " 06/01/2014 - "Moreover, an in vivo xenograft assay indicated that WK88-1 markedly suppressed tumor growth in the H1975 xenografts, highlighting the potential efficacy of WK88-1 for overcoming gefitinib resistance in NSCLCs harboring the T790M mutation in EGFR. " 10/01/2014 - "Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification."
2.	Lung Neoplasms (Lung Cancer) 10/01/2014 - "Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification."

Related Drugs and Biologics

1.	Gefitinib (Iressa)
2.	geldanamycin